Click for best price
Immunooncology Drugs Market Size, Share 2022
Market Analysis and Insights: Global Immunooncology Drugs Market
The global Immunooncology Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immunooncology Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immunooncology Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immunooncology Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immunooncology Drugs market.
Global Immunooncology Drugs Scope and Market Size
Immuno-oncology Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Immuno-oncology Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Immuno-oncology Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Immunooncology Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Immunooncology Drugs, with price, sales, revenue, and global market share of Immunooncology Drugs from 2019 to 2022.
Chapter 3, the Immunooncology Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Immunooncology Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Immunooncology Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Immunooncology Drugs.
Chapter 13, 14, and 15, to describe Immunooncology Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Immunooncology Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Immuno-oncology Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
127 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Immuno-oncology Drugs Product Introduction
1.2 Global Immuno-oncology Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Immuno-oncology Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Immuno-oncology Drugs Sales in Volume for the Year 2017-2028
1.3 United States Immuno-oncology Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Immuno-oncology Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Immuno-oncology Drugs Sales in Volume for the Year 2017-2028
1.4 Immuno-oncology Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Immuno-oncology Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Immuno-oncology Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Immuno-oncology Drugs Market Dynamics
1.5.1 Immuno-oncology Drugs Industry Trends
1.5.2 Immuno-oncology Drugs Market Drivers
1.5.3 Immuno-oncology Drugs Market Challenges
1.5.4 Immuno-oncology Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Immuno-oncology Drugs Market Segment by Type
2.1.1 Immune Checkpoint Inhibitors
2.1.2 Immune System Modulators
2.1.3 Cancer Vaccines
2.1.4 Oncolytic Virus
2.1.5 Others
2.2 Global Immuno-oncology Drugs Market Size by Type
2.2.1 Global Immuno-oncology Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Immuno-oncology Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Immuno-oncology Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Immuno-oncology Drugs Market Size by Type
2.3.1 United States Immuno-oncology Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Immuno-oncology Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Immuno-oncology Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Immuno-oncology Drugs Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Centers
3.2 Global Immuno-oncology Drugs Market Size by Application
3.2.1 Global Immuno-oncology Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Immuno-oncology Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Immuno-oncology Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Immuno-oncology Drugs Market Size by Application
3.3.1 United States Immuno-oncology Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Immuno-oncology Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Immuno-oncology Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Immuno-oncology Drugs Competitor Landscape by Company
4.1 Global Immuno-oncology Drugs Market Size by Company
4.1.1 Top Global Immuno-oncology Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Immuno-oncology Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Immuno-oncology Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Immuno-oncology Drugs Price by Manufacturer (2017-2022)
4.2 Global Immuno-oncology Drugs Concentration Ratio (CR)
4.2.1 Immuno-oncology Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Immuno-oncology Drugs in 2021
4.2.3 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Immuno-oncology Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Immuno-oncology Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Immuno-oncology Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Immuno-oncology Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Immuno-oncology Drugs Market Size by Company
4.5.1 Top Immuno-oncology Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Immuno-oncology Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Immuno-oncology Drugs Sales by Players (2020, 2021 & 2022)
5 Global Immuno-oncology Drugs Market Size by Region
5.1 Global Immuno-oncology Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Immuno-oncology Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Immuno-oncology Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Immuno-oncology Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Immuno-oncology Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Immuno-oncology Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Immuno-oncology Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Immuno-oncology Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Immuno-oncology Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Amgen, Inc
7.1.1 Amgen, Inc Corporation Information
7.1.2 Amgen, Inc Description and Business Overview
7.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered
7.1.5 Amgen, Inc Recent Development
7.2 AstraZeneca, Plc
7.2.1 AstraZeneca, Plc Corporation Information
7.2.2 AstraZeneca, Plc Description and Business Overview
7.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products Offered
7.2.5 AstraZeneca, Plc Recent Development
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Corporation Information
7.3.2 Bristol-Myers Squibb Description and Business Overview
7.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products Offered
7.3.5 Bristol-Myers Squibb Recent Development
7.4 Celgene Corporation
7.4.1 Celgene Corporation Corporation Information
7.4.2 Celgene Corporation Description and Business Overview
7.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Celgene Corporation Immuno-oncology Drugs Products Offered
7.4.5 Celgene Corporation Recent Development
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Corporation Information
7.5.2 Eli Lilly and Company Description and Business Overview
7.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Eli Lilly and Company Immuno-oncology Drugs Products Offered
7.5.5 Eli Lilly and Company Recent Development
7.6 Merck & Co.
7.6.1 Merck & Co. Corporation Information
7.6.2 Merck & Co. Description and Business Overview
7.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Merck & Co. Immuno-oncology Drugs Products Offered
7.6.5 Merck & Co. Recent Development
7.7 Hoffmann-La Roche AG
7.7.1 Hoffmann-La Roche AG Corporation Information
7.7.2 Hoffmann-La Roche AG Description and Business Overview
7.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products Offered
7.7.5 Hoffmann-La Roche AG Recent Development
7.8 Johnson & Johnson
7.8.1 Johnson & Johnson Corporation Information
7.8.2 Johnson & Johnson Description and Business Overview
7.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Johnson & Johnson Immuno-oncology Drugs Products Offered
7.8.5 Johnson & Johnson Recent Development
7.9 Novartis International AG
7.9.1 Novartis International AG Corporation Information
7.9.2 Novartis International AG Description and Business Overview
7.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Novartis International AG Immuno-oncology Drugs Products Offered
7.9.5 Novartis International AG Recent Development
7.10 AbbVie, Inc.
7.10.1 AbbVie, Inc. Corporation Information
7.10.2 AbbVie, Inc. Description and Business Overview
7.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 AbbVie, Inc. Immuno-oncology Drugs Products Offered
7.10.5 AbbVie, Inc. Recent Development
7.11 Pfizer Inc.
7.11.1 Pfizer Inc. Corporation Information
7.11.2 Pfizer Inc. Description and Business Overview
7.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Pfizer Inc. Immuno-oncology Drugs Products Offered
7.11.5 Pfizer Inc. Recent Development
7.12 Sanofi S.A.
7.12.1 Sanofi S.A. Corporation Information
7.12.2 Sanofi S.A. Description and Business Overview
7.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Sanofi S.A. Products Offered
7.12.5 Sanofi S.A. Recent Development
7.13 EMD Serono, Inc.
7.13.1 EMD Serono, Inc. Corporation Information
7.13.2 EMD Serono, Inc. Description and Business Overview
7.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 EMD Serono, Inc. Products Offered
7.13.5 EMD Serono, Inc. Recent Development
7.14 Gilead Sciences Inc.
7.14.1 Gilead Sciences Inc. Corporation Information
7.14.2 Gilead Sciences Inc. Description and Business Overview
7.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Gilead Sciences Inc. Products Offered
7.14.5 Gilead Sciences Inc. Recent Development
7.15 Prometheus Therapeutics & Diagnostics
7.15.1 Prometheus Therapeutics & Diagnostics Corporation Information
7.15.2 Prometheus Therapeutics & Diagnostics Description and Business Overview
7.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Prometheus Therapeutics & Diagnostics Products Offered
7.15.5 Prometheus Therapeutics & Diagnostics Recent Development
7.16 Aduro BioTech
7.16.1 Aduro BioTech Corporation Information
7.16.2 Aduro BioTech Description and Business Overview
7.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Aduro BioTech Products Offered
7.16.5 Aduro BioTech Recent Development
7.17 Galena Biopharma
7.17.1 Galena Biopharma Corporation Information
7.17.2 Galena Biopharma Description and Business Overview
7.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Galena Biopharma Products Offered
7.17.5 Galena Biopharma Recent Development
7.18 Bavarian Nordic
7.18.1 Bavarian Nordic Corporation Information
7.18.2 Bavarian Nordic Description and Business Overview
7.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Bavarian Nordic Products Offered
7.18.5 Bavarian Nordic Recent Development
7.19 Celldex Therapeutics
7.19.1 Celldex Therapeutics Corporation Information
7.19.2 Celldex Therapeutics Description and Business Overview
7.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Celldex Therapeutics Products Offered
7.19.5 Celldex Therapeutics Recent Development
7.20 ImmunoCellular Therapeutics
7.20.1 ImmunoCellular Therapeutics Corporation Information
7.20.2 ImmunoCellular Therapeutics Description and Business Overview
7.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.20.4 ImmunoCellular Therapeutics Products Offered
7.20.5 ImmunoCellular Therapeutics Recent Development
7.21 Incyte
7.21.1 Incyte Corporation Information
7.21.2 Incyte Description and Business Overview
7.21.3 Incyte Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.21.4 Incyte Products Offered
7.21.5 Incyte Recent Development
7.22 Dendreon Corporation
7.22.1 Dendreon Corporation Corporation Information
7.22.2 Dendreon Corporation Description and Business Overview
7.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.22.4 Dendreon Corporation Products Offered
7.22.5 Dendreon Corporation Recent Development
7.23 Agilent Technologies Inc.
7.23.1 Agilent Technologies Inc. Corporation Information
7.23.2 Agilent Technologies Inc. Description and Business Overview
7.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.23.4 Agilent Technologies Inc. Products Offered
7.23.5 Agilent Technologies Inc. Recent Development
7.24 Agenus Inc.
7.24.1 Agenus Inc. Corporation Information
7.24.2 Agenus Inc. Description and Business Overview
7.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.24.4 Agenus Inc. Products Offered
7.24.5 Agenus Inc. Recent Development
7.25 Enzo Biochem, Inc.
7.25.1 Enzo Biochem, Inc. Corporation Information
7.25.2 Enzo Biochem, Inc. Description and Business Overview
7.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.25.4 Enzo Biochem, Inc. Products Offered
7.25.5 Enzo Biochem, Inc. Recent Development
7.26 Lonza Group
7.26.1 Lonza Group Corporation Information
7.26.2 Lonza Group Description and Business Overview
7.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.26.4 Lonza Group Products Offered
7.26.5 Lonza Group Recent Development
7.27 Bio-Rad Laboratories, Inc.
7.27.1 Bio-Rad Laboratories, Inc. Corporation Information
7.27.2 Bio-Rad Laboratories, Inc. Description and Business Overview
7.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.27.4 Bio-Rad Laboratories, Inc. Products Offered
7.27.5 Bio-Rad Laboratories, Inc. Recent Development
7.28 Avantor, Inc.
7.28.1 Avantor, Inc. Corporation Information
7.28.2 Avantor, Inc. Description and Business Overview
7.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.28.4 Avantor, Inc. Products Offered
7.28.5 Avantor, Inc. Recent Development
7.29 Spring Bank Pharmaceuticals, Inc.
7.29.1 Spring Bank Pharmaceuticals, Inc. Corporation Information
7.29.2 Spring Bank Pharmaceuticals, Inc. Description and Business Overview
7.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.29.4 Spring Bank Pharmaceuticals, Inc. Products Offered
7.29.5 Spring Bank Pharmaceuticals, Inc. Recent Development
7.30 Ferring Pharmaceuticals
7.30.1 Ferring Pharmaceuticals Corporation Information
7.30.2 Ferring Pharmaceuticals Description and Business Overview
7.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022)
7.30.4 Ferring Pharmaceuticals Products Offered
7.30.5 Ferring Pharmaceuticals Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Immuno-oncology Drugs Industry Chain Analysis
8.2 Immuno-oncology Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Immuno-oncology Drugs Distributors
8.3 Immuno-oncology Drugs Production Mode & Process
8.4 Immuno-oncology Drugs Sales and Marketing
8.4.1 Immuno-oncology Drugs Sales Channels
8.4.2 Immuno-oncology Drugs Distributors
8.5 Immuno-oncology Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Immuno-oncology Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Immuno-oncology Drugs Market Trends
Table 3. Immuno-oncology Drugs Market Drivers
Table 4. Immuno-oncology Drugs Market Challenges
Table 5. Immuno-oncology Drugs Market Restraints
Table 6. Global Immuno-oncology Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Immuno-oncology Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Immuno-oncology Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Immuno-oncology Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Immuno-oncology Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Immuno-oncology Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Immuno-oncology Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Immuno-oncology Drugs Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Immuno-oncology Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Immuno-oncology Drugs Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Immuno-oncology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2021)
Table 18. Top Players of Immuno-oncology Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Immuno-oncology Drugs Product Type
Table 20. Date of International Manufacturers Enter into Immuno-oncology Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Immuno-oncology Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Immuno-oncology Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Immuno-oncology Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Immuno-oncology Drugs Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Immuno-oncology Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Immuno-oncology Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Immuno-oncology Drugs Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Immuno-oncology Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Immuno-oncology Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Immuno-oncology Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Immuno-oncology Drugs Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Immuno-oncology Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Amgen, Inc Corporation Information
Table 43. Amgen, Inc Description and Business Overview
Table 44. Amgen, Inc Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Amgen, Inc Immuno-oncology Drugs Product
Table 46. Amgen, Inc Recent Development
Table 47. AstraZeneca, Plc Corporation Information
Table 48. AstraZeneca, Plc Description and Business Overview
Table 49. AstraZeneca, Plc Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. AstraZeneca, Plc Product
Table 51. AstraZeneca, Plc Recent Development
Table 52. Bristol-Myers Squibb Corporation Information
Table 53. Bristol-Myers Squibb Description and Business Overview
Table 54. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Bristol-Myers Squibb Product
Table 56. Bristol-Myers Squibb Recent Development
Table 57. Celgene Corporation Corporation Information
Table 58. Celgene Corporation Description and Business Overview
Table 59. Celgene Corporation Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Celgene Corporation Product
Table 61. Celgene Corporation Recent Development
Table 62. Eli Lilly and Company Corporation Information
Table 63. Eli Lilly and Company Description and Business Overview
Table 64. Eli Lilly and Company Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Eli Lilly and Company Product
Table 66. Eli Lilly and Company Recent Development
Table 67. Merck & Co. Corporation Information
Table 68. Merck & Co. Description and Business Overview
Table 69. Merck & Co. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Merck & Co. Product
Table 71. Merck & Co. Recent Development
Table 72. Hoffmann-La Roche AG Corporation Information
Table 73. Hoffmann-La Roche AG Description and Business Overview
Table 74. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Hoffmann-La Roche AG Product
Table 76. Hoffmann-La Roche AG Recent Development
Table 77. Johnson & Johnson Corporation Information
Table 78. Johnson & Johnson Description and Business Overview
Table 79. Johnson & Johnson Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. Johnson & Johnson Product
Table 81. Johnson & Johnson Recent Development
Table 82. Novartis International AG Corporation Information
Table 83. Novartis International AG Description and Business Overview
Table 84. Novartis International AG Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Novartis International AG Product
Table 86. Novartis International AG Recent Development
Table 87. AbbVie, Inc. Corporation Information
Table 88. AbbVie, Inc. Description and Business Overview
Table 89. AbbVie, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. AbbVie, Inc. Product
Table 91. AbbVie, Inc. Recent Development
Table 92. Pfizer Inc. Corporation Information
Table 93. Pfizer Inc. Description and Business Overview
Table 94. Pfizer Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 95. Pfizer Inc. Product
Table 96. Pfizer Inc. Recent Development
Table 97. Sanofi S.A. Corporation Information
Table 98. Sanofi S.A. Description and Business Overview
Table 99. Sanofi S.A. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 100. Sanofi S.A. Product
Table 101. Sanofi S.A. Recent Development
Table 102. EMD Serono, Inc. Corporation Information
Table 103. EMD Serono, Inc. Description and Business Overview
Table 104. EMD Serono, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 105. EMD Serono, Inc. Product
Table 106. EMD Serono, Inc. Recent Development
Table 107. Gilead Sciences Inc. Corporation Information
Table 108. Gilead Sciences Inc. Description and Business Overview
Table 109. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 110. Gilead Sciences Inc. Product
Table 111. Gilead Sciences Inc. Recent Development
Table 112. Prometheus Therapeutics & Diagnostics Corporation Information
Table 113. Prometheus Therapeutics & Diagnostics Description and Business Overview
Table 114. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 115. Prometheus Therapeutics & Diagnostics Product
Table 116. Prometheus Therapeutics & Diagnostics Recent Development
Table 117. Aduro BioTech Corporation Information
Table 118. Aduro BioTech Description and Business Overview
Table 119. Aduro BioTech Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 120. Aduro BioTech Product
Table 121. Aduro BioTech Recent Development
Table 122. Galena Biopharma Corporation Information
Table 123. Galena Biopharma Description and Business Overview
Table 124. Galena Biopharma Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 125. Galena Biopharma Product
Table 126. Galena Biopharma Recent Development
Table 127. Bavarian Nordic Corporation Information
Table 128. Bavarian Nordic Description and Business Overview
Table 129. Bavarian Nordic Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 130. Bavarian Nordic Product
Table 131. Bavarian Nordic Recent Development
Table 132. Celldex Therapeutics Corporation Information
Table 133. Celldex Therapeutics Description and Business Overview
Table 134. Celldex Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 135. Celldex Therapeutics Product
Table 136. Celldex Therapeutics Recent Development
Table 137. ImmunoCellular Therapeutics Corporation Information
Table 138. ImmunoCellular Therapeutics Description and Business Overview
Table 139. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 140. ImmunoCellular Therapeutics Product
Table 141. ImmunoCellular Therapeutics Recent Development
Table 142. Incyte Corporation Information
Table 143. Incyte Description and Business Overview
Table 144. Incyte Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 145. Incyte Product
Table 146. Incyte Recent Development
Table 147. Dendreon Corporation Corporation Information
Table 148. Dendreon Corporation Description and Business Overview
Table 149. Dendreon Corporation Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 150. Dendreon Corporation Product
Table 151. Dendreon Corporation Recent Development
Table 152. Agilent Technologies Inc. Corporation Information
Table 153. Agilent Technologies Inc. Description and Business Overview
Table 154. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 155. Agilent Technologies Inc. Product
Table 156. Agilent Technologies Inc. Recent Development
Table 157. Agenus Inc. Corporation Information
Table 158. Agenus Inc. Description and Business Overview
Table 159. Agenus Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 160. Agenus Inc. Product
Table 161. Agenus Inc. Recent Development
Table 162. Enzo Biochem, Inc. Corporation Information
Table 163. Enzo Biochem, Inc. Description and Business Overview
Table 164. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 165. Enzo Biochem, Inc. Product
Table 166. Enzo Biochem, Inc. Recent Development
Table 167. Lonza Group Corporation Information
Table 168. Lonza Group Description and Business Overview
Table 169. Lonza Group Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 170. Lonza Group Product
Table 171. Lonza Group Recent Development
Table 172. Bio-Rad Laboratories, Inc. Corporation Information
Table 173. Bio-Rad Laboratories, Inc. Description and Business Overview
Table 174. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 175. Bio-Rad Laboratories, Inc. Product
Table 176. Bio-Rad Laboratories, Inc. Recent Development
Table 177. Avantor, Inc. Corporation Information
Table 178. Avantor, Inc. Description and Business Overview
Table 179. Avantor, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 180. Avantor, Inc. Product
Table 181. Avantor, Inc. Recent Development
Table 182. Spring Bank Pharmaceuticals, Inc. Corporation Information
Table 183. Spring Bank Pharmaceuticals, Inc. Description and Business Overview
Table 184. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 185. Spring Bank Pharmaceuticals, Inc. Product
Table 186. Spring Bank Pharmaceuticals, Inc. Recent Development
Table 187. Ferring Pharmaceuticals Corporation Information
Table 188. Ferring Pharmaceuticals Description and Business Overview
Table 189. Ferring Pharmaceuticals Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 190. Ferring Pharmaceuticals Product
Table 191. Ferring Pharmaceuticals Recent Development
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Immuno-oncology Drugs Customers List
Table 195. Immuno-oncology Drugs Distributors List
Table 196. Research Programs/Design for This Report
Table 197. Key Data Information from Secondary Sources
Table 198. Key Data Information from Primary Sources
List of Figures
Figure 1. Immuno-oncology Drugs Product Picture
Figure 2. Global Immuno-oncology Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Immuno-oncology Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Immuno-oncology Drugs Sales 2017-2028 (K Units)
Figure 5. United States Immuno-oncology Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Immuno-oncology Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Immuno-oncology Drugs Sales 2017-2028 (K Units)
Figure 8. United States Immuno-oncology Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Immuno-oncology Drugs Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Immuno-oncology Drugs Report Years Considered
Figure 11. Product Picture of Immune Checkpoint Inhibitors
Figure 12. Product Picture of Immune System Modulators
Figure 13. Product Picture of Cancer Vaccines
Figure 14. Product Picture of Oncolytic Virus
Figure 15. Product Picture of Others
Figure 16. Global Immuno-oncology Drugs Market Share by Type in 2022 & 2028
Figure 17. Global Immuno-oncology Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 18. Global Immuno-oncology Drugs Sales Market Share in Value by Type (2017-2028)
Figure 19. Global Immuno-oncology Drugs Sales by Type (2017-2028) & (K Units)
Figure 20. Global Immuno-oncology Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 21. Global Immuno-oncology Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 22. United States Immuno-oncology Drugs Market Share by Type in 2022 & 2028
Figure 23. United States Immuno-oncology Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 24. United States Immuno-oncology Drugs Sales Market Share in Value by Type (2017-2028)
Figure 25. United States Immuno-oncology Drugs Sales by Type (2017-2028) & (K Units)
Figure 26. United States Immuno-oncology Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 27. United States Immuno-oncology Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 28. Product Picture of Hospitals
Figure 29. Product Picture of Clinics
Figure 30. Product Picture of Ambulatory Surgical Centers
Figure 31. Global Immuno-oncology Drugs Market Share by Application in 2022 & 2028
Figure 32. Global Immuno-oncology Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 33. Global Immuno-oncology Drugs Sales Market Share in Value by Application (2017-2028)
Figure 34. Global Immuno-oncology Drugs Sales by Application (2017-2028) & (K Units)
Figure 35. Global Immuno-oncology Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 36. Global Immuno-oncology Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 37. United States Immuno-oncology Drugs Market Share by Application in 2022 & 2028
Figure 38. United States Immuno-oncology Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 39. United States Immuno-oncology Drugs Sales Market Share in Value by Application (2017-2028)
Figure 40. United States Immuno-oncology Drugs Sales by Application (2017-2028) & (K Units)
Figure 41. United States Immuno-oncology Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 42. United States Immuno-oncology Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 43. North America Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 44. North America Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 45. U.S. Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Canada Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. Europe Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 48. Europe Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 49. Germany Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. France Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. U.K. Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Italy Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Russia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Asia-Pacific Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 55. Asia-Pacific Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 56. China Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Japan Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. South Korea Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. India Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Australia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Taiwan Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Indonesia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Thailand Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Malaysia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Philippines Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Latin America Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 67. Latin America Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 68. Mexico Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Brazil Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Argentina Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Middle East & Africa Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 72. Middle East & Africa Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 73. Turkey Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Saudi Arabia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. U.A.E Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. Immuno-oncology Drugs Value Chain
Figure 77. Immuno-oncology Drugs Production Process
Figure 78. Channels of Distribution
Figure 79. Distributors Profiles
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
